Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
February 23, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom new drug application filing in the first half of 2023Madrigal reports year end cash, cash...
Theratechnologies présente de nouvelles données sur la tésamoréline démontrant une amélioration du syndrome métabolique chez les personnes vivant avec le VIH
February 22, 2023 17:30 ET
|
Theratechnologies
Une présentation à la « Conference on Retroviruses and Opportunistic Infections (CROI) » démontrant une association entre la réduction de l’excès de gras viscéral abdominal et la diminution de la...
Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
February 22, 2023 17:30 ET
|
Theratechnologies
Presentation at Conference on Retroviruses and Opportunistic Infections (CROI) demonstrates association between excess visceral abdominal fat (EVAF) reduction and decreased prevalence of metabolic...
Correction: Inventiva publie ses résultats financiers préliminaires pour l’exercice 2022¹
February 14, 2023 17:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, Etats-Unis), le 14 février 2023 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement...
Correction: Inventiva reports preliminary financial results for Full-Year 2022¹
February 14, 2023 17:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
Inventiva publie ses résultats financiers préliminaires pour l’exercice 2022¹
February 14, 2023 16:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, Etats-Unis), le 14 février 2023 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement...
Inventiva reports preliminary financial results for Full-Year 2022¹
February 14, 2023 16:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
February 08, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
January 06, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of...
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
January 04, 2023 16:00 ET
|
INVENTIVA
Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to...